The first forthcoming trial purposely designed in order to estimate erectile function in patients with erectile dysfunction (ED) and with dyslipidemia was recently conducted. Its results show that LEVITRA (vardenafil), that is used to treat ED, considerably improves the ability of a man with these problems to reach and sustain an erection in order to have successful intercourse. These results were presented at the annual fall Meeting of the Sexual Medicine Society of North America (SMSNA) that was taken place in Chicago.

The placebo-controlled, randomized, double-blind study is the first investigation to evaluate the efficacy and safety of a phosphodiesterase type 5 inhibitor in a group of men with erectile dysfunction and dyslipidemia. 395 men took place in this study. Its results show that Levitra considerably increased penetration rates (SEP2, a rating system measuring penetration) and the ability to sustain an erection (SEP3, a rating system measuring maintenance of erection) in comparison with placebo.

“Impotence is usually connected with high level of cholesterol, nevertheless a number of physicians aren’t treating erectile dysfunction, a life-changing condition,” noted Dr. Martin Miner, Clinical Assistant Professor Family Medicine at the Warren Alpert Medical School of Brown University. “This study offers more support that Levitra treats ED successfully, even if a man experiences a serious frequent disease such as the presence of high levels of cholesterol in the blood.”

Almost 70% of the estimated thirty million men in the USA with erectile dysfunction have also other frequent diseases, for example, dyslipidemia, diabetes, or hypertension that can result in ED. Previous investigations have shown that the LEVITRA safety and efficacy in men with erectile dysfunction who have diabetes or arterial hypertension as well.

The double-blind, randomized, placebo-controlled, fixed-dose study enrolled 395 men with ages from 18 to 64 who experienced dyslipidemia and erectile dysfunction, they were treated with placebo or Levitra for twelve weeks.

Men taken Levitra had clinically meaningful and statistically important improvements in SEP2 scores and SEP3 scores opposed to placebo (79.1 percent and 66.7 percent for Levitra, respectively, versus 51.9 percent and 33.8 percent for placebo). Furthermore, International Index of Erectile Function (IIEF-EF) scores were considerably higher for the men treated with LEVITRA in comparison with the group taken placebo. These scores are estimated according to a questionnaire of a patient and their every day diary answer to specific queries about their sexual performance.

Levitra was tolerated well. Several side effects (happening in about 5 percent of patients) were headaches (Levitra is 9%, placebo is 1%) and upper respiratory tract infections (for Levitra 5%, for placebo 3%).

Erectile dysfunction is the recurrent or consistent male inability to achieve and/or sustain an erection that is sufficient for sexual intercourse. Erectile dysfunction may be an inconsistent ability to attain a penile erection, a total inability to do this, or a tendency to maintain short-term erections. It is founded out that some ED degree has an effect on as many as thirty million men in the USA.

Some of the most general treatments for erectile dysfunction are lifestyle adjustments and good control of concomitant health conditions and also the oral medicines usage or other therapies. Treating that corresponds to medical conditions or reduces stress can help to sustain erectile function.

LEVITRA (vardenafil) is a drug that should be prescribed by a doctor for treating erectile dysfunction. Consistent with the phosphodiesterase type 5 inhibitor (PDE5 inhibition) effects, prescription of Levitra together with nitric oxide and nitrates donors is strictly contraindicated.

It’s necessary to be cautious if PDE5 inhibitors, such as Levitra, are taken concurrently with steady alpha blocker therapy, due to arterial pressure lowering.

Levitra isn’t recommended for those patients who have uncontrolled high blood pressure (more than 170/110 mmHg).

If a man has cardiovascular disease and sexual activity isn’t recommended for him, any medication for ED, as well as LEVITRA, shouldn’t be used as a rule.

Patients who take CYP3A4 inhibitors (for example, saquinavir,indinavir, ritonavir,atazanavir, itraconazole, clarithromycin , ketoconazole, and erythromycin), are recommended lower LEVITRA doses, and time between these doses should be extended. See prescribing dosage information for LEVITRA.

During clinical trials, the most regularly reported side effects using LEVITRA were rhinitis, headache, and flushing. Side effects were transient in general.

It’s been rarely reported about non-arteritic anterior ischemic optic neuropathy (NAION) post-marketing in temporary connection with the usage of PDE5 inhibitors, such as Levitra. Abrupt loss of hearing, occasionally with dizziness and tinnitus, has also been reported seldom in temporary connection with the PDE5 inhibitors usage, including Levitra. It is hard to determine if these effects are connected with PDE5 inhibitors or with some other things. General practitioners ought to advise their patients to give up taking PDE5 inhibitors, counting Levitra, and look for rapid medical attention if these events such as sudden loss of hearing or vision take place.

The recommended initial Levitra dose is 10 mg. Dose down to 5 mg or up to 20 mg depending on its efficacy and certainly, side effects.

The maximum frequency of the drug usage is once a day. Levitra is accessible in 2.5mg, 5mg, 10mg and 20mg pills.